日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity

具有抗肿瘤和抗血管生成活性的新型 PERK 激酶抑制剂的表征

Charity Atkins, Qi Liu, Elisabeth Minthorn, Shu-Yun Zhang, David J Figueroa, Katherine Moss, Thomas B Stanley, Brent Sanders, Aaron Goetz, Nathan Gaul, Anthony E Choudhry, Hasan Alsaid, Beat M Jucker, Jeffrey M Axten, Rakesh Kumar

Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK)

发现 7-甲基-5-(1-{[3-(三氟甲基)苯基]乙酰基}-2,3-二氢-1H-吲哚-5-基)-7H-吡咯并[2,3-d]嘧啶-4-胺 (GSK2606414),一种强效且选择性的蛋白激酶 R (PKR) 样内质网激酶 (PERK) 抑制剂

Jeffrey M Axten, Jesús R Medina, Yanhong Feng, Arthur Shu, Stuart P Romeril, Seth W Grant, William Hoi Hong Li, Dirk A Heerding, Elisabeth Minthorn, Thomas Mencken, Charity Atkins, Qi Liu, Sridhar Rabindran, Rakesh Kumar, Xuan Hong, Aaron Goetz, Thomas Stanley, J David Taylor, Scott D Sigethy, Ginge